Since it was founded in 1986,
Centaur, Inc.’s business focus has been
concentrated in adaptations of proven new
technology -- with special emphasis in
biotechnology -- converting successes from the
human healthcare market to address similar
problems in the animal health
Centaur’s first products of
prominence were concentrated in the equine market,
and focused on diagnostic technologies that were
representative of ‘breakthrough
innovations’. One such product
is the Equine Infectious Anemia (EIA) diagnostic
that was adapted from the human AIDS test and for
which a patent was granted in 1995.
Centaur, Inc. (Centaur) and
United Agriculture and Veterinary Products, Inc.
(Unavet) were two separate Kansas City based
animal health businesses that have been
operational since the mid 1980’s.
Both companies had been engaged in sales
activity in separate but complimentary
segments of the animal health market.
The merging of the two existing companies
in 2001 provided efficiencies and growth
opportunities available that
would not have been available to either company
Centaur has intentionally
limited its pharmaceutical distributors to provide
nation-wide coverage, but ideally with only 2 to 3
distributorships in the same geographical area.
This has not only intensified sales
presentations to targeted accounts, but has also
decreased the solicitation of orders based upon
selling price alone.
The Company also maintains
the right to sell its products direct, (as is
required by the USDA on the EIA tests), should an
interested laboratory or veterinarian not wish to
deal with one of the select pharmaceutical
distributors. Centaur’s ‘direct
customer base’ currently numbers approximately
1000 accounts, with Centaur currently stocking,
shipping and billing its EIA tests to
approximately 200 of the 500 USDA approved